Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients

The aim of this study was to investigate whether hypermethylation of Eyes Absent 4 (EYA4) is also implicated in Iranian Colorectal Cancer (CRC) patients or not. From fresh frozen tissues, samples from 38 paired (cancer and normal) CRC tissue specimens were used in this study, the DNA was isolated,...

Full description

Bibliographic Details
Main Authors: Matineh Barati Bagerabad, Sahar Tavakolian, Mohammad Reza Abbaszadegan, Mohammad Amin Kerachian
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2018-02-01
Series:Acta Medica Iranica
Subjects:
Online Access:https://acta.tums.ac.ir/index.php/acta/article/view/6312
id doaj-8d6a9aa2bf2c43898be964b64cc4c3db
record_format Article
spelling doaj-8d6a9aa2bf2c43898be964b64cc4c3db2020-11-25T02:53:54ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942018-02-015615251Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer PatientsMatineh Barati Bagerabad0Sahar Tavakolian1Mohammad Reza Abbaszadegan2Mohammad Amin Kerachian3Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Biology, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran.Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Biology, University of Sistan and Balouchestan, Zahedan, Iran.Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AND Cancer Genetics Research Unit, Reza Radiotherapy and Oncology Center, Mashhad, Iran. The aim of this study was to investigate whether hypermethylation of Eyes Absent 4 (EYA4) is also implicated in Iranian Colorectal Cancer (CRC) patients or not. From fresh frozen tissues, samples from 38 paired (cancer and normal) CRC tissue specimens were used in this study, the DNA was isolated, sodium bisulfite treated and analyzed by methylation-specific polymerase (MSP) chain reaction using primers specific for unmethylated or methylated promoter sequences of the EYA4 gene. We also analyzed EYA4 mRNA expression using real time RT-PCR. Demographic characteristics of these patients including age, sex, tumor grade, location, stage, and TNM classification were evaluated and the relationship between methylation status of the gene and clinicopathological features was analyzed. Current study indicated that EYA4 promoter hypermethylation has a sensitivity of 81.57% and specificity of 78.94%. Findings showed lower expression of EYA-4 in methylated samples in comparison with its normal adjacent tissue, although it was not significant (P>0.05). No significant associations were observed between EYA4 hypermethylation and the clinicopathological characteristics. Although the clinical patient outcome of our 38 CRC patients was not associated with EYA4 promoter hypermethylation, the high frequency of this methylation and its high sensitivity and specificity to neoplastic cells may qualify EYA4 promoter methylation as a potential candidate screening marker in Iranian population and may help to improve early detection of CRC. https://acta.tums.ac.ir/index.php/acta/article/view/6312DNA methylationColorectal cancerEYA4Screening
collection DOAJ
language English
format Article
sources DOAJ
author Matineh Barati Bagerabad
Sahar Tavakolian
Mohammad Reza Abbaszadegan
Mohammad Amin Kerachian
spellingShingle Matineh Barati Bagerabad
Sahar Tavakolian
Mohammad Reza Abbaszadegan
Mohammad Amin Kerachian
Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
Acta Medica Iranica
DNA methylation
Colorectal cancer
EYA4
Screening
author_facet Matineh Barati Bagerabad
Sahar Tavakolian
Mohammad Reza Abbaszadegan
Mohammad Amin Kerachian
author_sort Matineh Barati Bagerabad
title Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
title_short Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
title_full Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
title_fullStr Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
title_full_unstemmed Promoter Hypermethylation of the Eyes Absent 4 Gene is a Tumor-Specific Epigenetic Biomarker in Iranian Colorectal Cancer Patients
title_sort promoter hypermethylation of the eyes absent 4 gene is a tumor-specific epigenetic biomarker in iranian colorectal cancer patients
publisher Tehran University of Medical Sciences
series Acta Medica Iranica
issn 0044-6025
1735-9694
publishDate 2018-02-01
description The aim of this study was to investigate whether hypermethylation of Eyes Absent 4 (EYA4) is also implicated in Iranian Colorectal Cancer (CRC) patients or not. From fresh frozen tissues, samples from 38 paired (cancer and normal) CRC tissue specimens were used in this study, the DNA was isolated, sodium bisulfite treated and analyzed by methylation-specific polymerase (MSP) chain reaction using primers specific for unmethylated or methylated promoter sequences of the EYA4 gene. We also analyzed EYA4 mRNA expression using real time RT-PCR. Demographic characteristics of these patients including age, sex, tumor grade, location, stage, and TNM classification were evaluated and the relationship between methylation status of the gene and clinicopathological features was analyzed. Current study indicated that EYA4 promoter hypermethylation has a sensitivity of 81.57% and specificity of 78.94%. Findings showed lower expression of EYA-4 in methylated samples in comparison with its normal adjacent tissue, although it was not significant (P>0.05). No significant associations were observed between EYA4 hypermethylation and the clinicopathological characteristics. Although the clinical patient outcome of our 38 CRC patients was not associated with EYA4 promoter hypermethylation, the high frequency of this methylation and its high sensitivity and specificity to neoplastic cells may qualify EYA4 promoter methylation as a potential candidate screening marker in Iranian population and may help to improve early detection of CRC.
topic DNA methylation
Colorectal cancer
EYA4
Screening
url https://acta.tums.ac.ir/index.php/acta/article/view/6312
work_keys_str_mv AT matinehbaratibagerabad promoterhypermethylationoftheeyesabsent4geneisatumorspecificepigeneticbiomarkeriniraniancolorectalcancerpatients
AT sahartavakolian promoterhypermethylationoftheeyesabsent4geneisatumorspecificepigeneticbiomarkeriniraniancolorectalcancerpatients
AT mohammadrezaabbaszadegan promoterhypermethylationoftheeyesabsent4geneisatumorspecificepigeneticbiomarkeriniraniancolorectalcancerpatients
AT mohammadaminkerachian promoterhypermethylationoftheeyesabsent4geneisatumorspecificepigeneticbiomarkeriniraniancolorectalcancerpatients
_version_ 1724723626887872512